Section 126-A:15-b - [Repealed Effective 10/1/2028] Committee On Emerging Medical TechnologiesI. There is established the joint committee on emerging medical technologies.II. The members of the committee shall be as follows: (a) One member of the senate, appointed by the senate president. The senate president also shall appoint one alternate member.(b) Two members of the house of representatives and 2 alternates, with one member and one alternate appointed by the speaker of the house of representatives and one member and one alternate appointed by the minority leader. If the speaker of the house of representatives is a member of the minority party, the second member and alternate shall be appointed by the majority leader. (c) Alternate members may attend committee meetings but shall not serve as voting members or count toward the committee's quorum unless a regular member is not in attendance.(d) A quorum shall be defined as 2 members, and shall not be required except to vote on recommendations.III. The committee shall solicit information and testimony from the public, state agencies, the attorney general, industry representatives with a special focus on medical and technical knowledge and challenges, health care providers and their associations, insurance companies, patient and consumer advocacy groups and any others who have an interest in emerging medical technologies.IV. Members of the committee shall receive mileage at the legislative rate when attending to the duties of the committee.V. The committee shall:(a) Review topics of public interest surrounding the availability of emerging medical technologies including but not limited to: (1) Expanding access to clinical trials in both academic and community settings;(2) The role of biomarkers;(3) Pursuing access through compassionate care programs for medically appropriate patients; and(4) Removing barriers to access for emerging medical technologies.(b) Review safety of emerging medical technologies including but not limited to: (1) Working with the board of medicine to find appropriate ways to identify safety risks of emerging technologies, and in particular implantable medical devices, including an early warning system for surgeons or interventionalists who experience higher than expected adverse events or implant failures in order to facilitate remediation or other efforts to protect the health and safety of the public;(2) Identifying safety signals in available data which warrant investigation, and identification of the appropriate body to conduct such an investigation; and(3) Policies, laws or administrative rules which impact the public disclosure or withholding of safety concerns surrounding emerging medical technologies.(c) Study barriers to expanding the presence of emerging medical technology companies and their suppliers in New Hampshire.(d) Other issues surrounding emerging medical technology, as deemed relevant by the committee.(e) Make specific recommendations regarding legislation or investigation relative to emerging medical technologies. The committee may make such recommendations as needed.VI. The first meeting of the committee shall be called by the first named representative. The first meeting of the committee shall be held within 60 days of the effective date of this section and the members of the committee shall elect a chairperson of committee from the members. The committee shall meet at least once a year and at such additional times as may be determined necessary by the chairperson. VII. Beginning October 1, 2023 and annually thereafter, the committee shall report its findings and any recommendations for proposed legislation to the chairmen and vice chairmen of the house health human services and elderly affairs committee, the senate health and human services committee, the oversight committee on health and human services, the speaker of the house of representatives, the president of the senate, the house clerk, the senate clerk, the governor, and the state library.Repealed by 2023, 128: 3, eff. 10/1/2028.Added by 2023, 128: 2, eff. 6/30/2023.